Table 8. Recommendations – follow-up.

Follow-up on men on testosterone therapy	LoE	Grade
Assess the response to therapy at 3, 6 to 12 months, and every 12 months thereafter	4	C
Aim for a target level of total testosterone 15–30 nmol/L to achieve optimal response	4	C
Monitor haematocrit before treatment, at 3–6 months, 12 months and every 12 months thereafter. Decrease dosage, or switch preparation, if haematocrit >0.54. If haematocrit remains elevated, consider stopping and re-introduce at a lower dose	4	C
Assess prostate health by PSA and, ideally, DRE before commencing TRT followed by PSA at 3–6 months, 12 months and every 12 months thereafter	4	C
Assess cardiovascular risk before TRT is initiated and monitor cardiovascular risk factors throughout therapy	1b	A

PSA: prostate specific antigen, DRE: digital rectal examination, TRT: testosterone replacement therapy.